Page History
Session Summary
The use of i2b2 for determining feasibility of clinical studies and clinical trials, focusing on the use of i2b2 in networks across the country, and novel approaches to allowing investigators to perform feasibility studies using i2b2-based client tools.
Section | |||||
---|---|---|---|---|---|
|
P1: SHRINE Update
- Review of all the new features added to the SHRINE Software
View Presentation
Douglas MacFadden
Chief Informatics Officer
Harvard Catalyst
P2: Using SHRINE and i2b2 for Feasibility Studies
|
Nich Wattanasin, MS
Corporate Team Lead
Partners HealthCare
|
View Presentation
|
|
Jack London, MD
P3:
|
|